Northland Securities restated their buy rating on shares of STRATA Skin Sciences (NASDAQ:SSKN) in a research note issued to investors on Tuesday morning, AnalystRatings.com reports. They currently have a $7.00 target price on the medical device company’s stock.
“We note that fully audited results for Q4-18 and Q1-19 are not available, and there seems to be a delay in the filing of docs, due primarily to some discrepancies related to historical contingent and potential liabilities relates to state sales and use taxes, and some non-cash derivative acctg treatment for debentures issued in 2015. Hence, our models still do not reflect the actuals for the reasons cited above.”,” the firm’s analyst commented.
Separately, ValuEngine downgraded STRATA Skin Sciences from a buy rating to a hold rating in a research note on Monday, April 1st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. STRATA Skin Sciences presently has an average rating of Buy and an average target price of $4.92.
Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of STRATA Skin Sciences by 3,605.7% in the 3rd quarter. Vanguard Group Inc. now owns 593,357 shares of the medical device company’s stock worth $2,100,000 after purchasing an additional 577,345 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of STRATA Skin Sciences by 70.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 66,813 shares of the medical device company’s stock worth $237,000 after purchasing an additional 27,586 shares during the period. Nantahala Capital Management LLC raised its holdings in shares of STRATA Skin Sciences by 8.2% in the 4th quarter. Nantahala Capital Management LLC now owns 2,768,001 shares of the medical device company’s stock worth $7,197,000 after purchasing an additional 209,110 shares during the period. Vanguard Group Inc raised its holdings in shares of STRATA Skin Sciences by 3,605.7% in the 3rd quarter. Vanguard Group Inc now owns 593,357 shares of the medical device company’s stock worth $2,100,000 after purchasing an additional 577,345 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of STRATA Skin Sciences in the 1st quarter worth approximately $39,000. 28.23% of the stock is currently owned by institutional investors.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
Featured Article: Benefits of owning preferred stock
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.